Press releases
- Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
- Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
- Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
- Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
- Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
- Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
- Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
- First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com
- Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
- Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"
More ▼
Key statistics
As of last trade Quest Diagnostics Inc (QDI:STU) traded at 119.00, 4.98% above its 52-week low of 113.35, set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 120.05 |
---|---|
High | 120.05 |
Low | 119.00 |
Bid | 117.60 |
Offer | 120.70 |
Previous close | 119.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 111.06m |
Free float | 110.58m |
P/E (TTM) | 16.96 |
Market cap | 14.10bn USD |
EPS (TTM) | 7.49 USD |
Annual div (ADY) | 2.77 EUR |
---|---|
Annual div yield (ADY) | 2.31% |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 22 2024 |
Data delayed at least 15 minutes, as of Apr 17 2024.
More ▼